Astellas Gets Exclusive Option To Diannexin Rights From Alavita
This article was originally published in PharmAsia News
Executive Summary
Astellas has agreed to pay $5 million for an exclusive option to acquire all assets and rights to diannexin from Mountain View, CA-based Alavita Pharmaceuticals